Health
Partnership to develop head and neck cancer vaccine – Mirage News
Professor Christian Ottensmeier (centre)Cancer Research UK, the University of Southampton and Touchlight Genetics (a London based biotechnology company)…
Professor Christian Ottensmeier (centre)
Cancer Research UK, the University of Southampton and Touchlight Genetics (a London based biotechnology company) have announced a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
HNSCC is the UK’s eighth most common cancer, but treatment options are limited and around 4,000 of those affected in the UK die each year. Whilst exis…
-
Noosa News23 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News22 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
Business9 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General18 hours ago‘Potential’ hacker contacts Qantas over data breach